91日本在线,午夜a级片,欧美视频专区一二在线观看

Global Biopharma Layoffs March 2026 Layoffs Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Merck Full Year 2025 Financial Report Merck Merck's 2025 performance shows 1% revenue growth, driven by strong sales of KEYTRUDA, new products like WINREVAIR, and growth in animal health. The company maintains cautious optimism for 2026 amid challenges like patent cliffs and currency fluctuations.
Global Biopharma Layoffs November 2025 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs September 2025 Layoffs The biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
Global Biopharma Layoffs August 2025 Layoffs The biopharmaceutical industry sees major August layoffs, with companies like Moderna, Merck cutting jobs amid restructurings, trial setbacks, and M&A activity.
Global Biopharma Layoffs July 2025 Layoffs Biopharmaceutical industry sees major July layoffs, with companies like Sarepta, GSK, Century, and Sage Therapeutics cutting jobs amid restructurings, trial setbacks, and M&A activity.
Merck KGaA Lupus Drug Trial Update: Enpatoran Phase 2 Insights Merck Merck KGaA reveals detailed results from its phase 2 lupus trial of enpatoran, highlighting mixed outcomes in different patient cohorts and plans to pursue regulatory approval based on promising secondary endpoint data.
Merck Advances Oral PCSK9 Inhibitor with Phase 3 Success Merck Merck achieves successful phase 3 trial results for enlicitide, an oral PCSK9 inhibitor, showing significant cholesterol reduction and a strong safety profile, advancing toward potential 2027 approval.
MoonLake Immunotherapeutics Rejects Merck's $3B Buyout Amid Promising IL-17 Pipeline Merck MoonLake Immunotherapeutics has rejected Merck’s $3B acquisition offer, choosing to advance its promising IL-17A/F antibody Sonelokimab, now in Phase III trials for autoimmune diseases like HS and PsA.
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Filing After Trial Misses Survival Goal Biotech Merck and Daiichi Sankyo have withdrawn their FDA application for patritumab deruxtecan after a Phase III trial failed to show significant overall survival benefits in EGFR-mutated NSCLC patients, citing regulatory discussions.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a